We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Retain Universal Health (UHS) Stock in Portfolio?
Read MoreHide Full Article
Universal Health Services, Inc. (UHS - Free Report) stock has gained 9% in last three months, outperforming the Zacks Hospitals industry’s increase of 7.6%. Although the prospects of the medical sector is currently shrouded in uncertainty owing to President Donald Trump’s decision of repealing and replacing Obamacare, Universal Health continues to progress on the back of several positives.
Driven by the company’s inorganic growth initiatives, revenues have been rising continuously. Strategic acquisitions and mergers also contribute to Universal Health’s growth trajectory. During 2016, the company spent $614 million to acquire the adult services division of Cambian Group, PLC in the U.K. The company also purchased Pahrump, NV-based Desert View Hospital as well as various other businesses and real property assets in the same year.
In addition, the company has carved a niche in providing care to underprivileged patients at low costs. Its acute care platform continues to deliver strong underwriting results year after year. Net revenue from acute care hospitals, outpatient facilities and commercial health insurer, accounted for 52% of the company’s consolidated net revenue during 2016, up 100 basis points (bps) year over year.
However, the company’s high debt level raises concerns. At the end of 2016, Universal Health’s long-term debt increased 20% over 2015 to $4 billion. This led to a deterioration of 300 bps year over year in debt-to-capital ratio to 48%.
Another area of concern for the company is the continuous increase in its operating expenses since 2013. In the year 2016, Universal Health witnessed 9% year-over-year increase in operating expenses of $8.5 billion, which accounted for 86.9% of net revenues. The company needs to undertake effective cost management to stop expenses from draining margin.
Also, the stock seems to be overvalued from certain aspects. Its Price to Cash Flow (PCF) ratio of 11.4 is significantly higher than the industry level of 5.6. Its Price to Sales (PS) ratio of 1.12 is above that industry average of 0.76.
Zacks Rank and Stocks to Consider:
Universal Health presently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the same space areUnitedHealth Group, Inc. (UNH - Free Report) , Inogen Inc. (INGN - Free Report) and Infinity Pharmaceuticals, Inc. . While Inogen and Infinity sport a Zacks Rank #1 (Strong Buy), UnitedHealth holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen posted positive surprises in three of the last four quarters with an average positive surprise of 49.08%.
Infinity delivered positive surprises in the trailing four quarters with an average beat of 28.38%.
UnitedHealth delivered positive surprises in last four quarters with an average beat of 3.80%.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public. Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Should You Retain Universal Health (UHS) Stock in Portfolio?
Universal Health Services, Inc. (UHS - Free Report) stock has gained 9% in last three months, outperforming the Zacks Hospitals industry’s increase of 7.6%. Although the prospects of the medical sector is currently shrouded in uncertainty owing to President Donald Trump’s decision of repealing and replacing Obamacare, Universal Health continues to progress on the back of several positives.
Driven by the company’s inorganic growth initiatives, revenues have been rising continuously. Strategic acquisitions and mergers also contribute to Universal Health’s growth trajectory. During 2016, the company spent $614 million to acquire the adult services division of Cambian Group, PLC in the U.K. The company also purchased Pahrump, NV-based Desert View Hospital as well as various other businesses and real property assets in the same year.
In addition, the company has carved a niche in providing care to underprivileged patients at low costs. Its acute care platform continues to deliver strong underwriting results year after year. Net revenue from acute care hospitals, outpatient facilities and commercial health insurer, accounted for 52% of the company’s consolidated net revenue during 2016, up 100 basis points (bps) year over year.
However, the company’s high debt level raises concerns. At the end of 2016, Universal Health’s long-term debt increased 20% over 2015 to $4 billion. This led to a deterioration of 300 bps year over year in debt-to-capital ratio to 48%.
Another area of concern for the company is the continuous increase in its operating expenses since 2013. In the year 2016, Universal Health witnessed 9% year-over-year increase in operating expenses of $8.5 billion, which accounted for 86.9% of net revenues. The company needs to undertake effective cost management to stop expenses from draining margin.
Also, the stock seems to be overvalued from certain aspects. Its Price to Cash Flow (PCF) ratio of 11.4 is significantly higher than the industry level of 5.6. Its Price to Sales (PS) ratio of 1.12 is above that industry average of 0.76.
Zacks Rank and Stocks to Consider:
Universal Health presently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the same space areUnitedHealth Group, Inc. (UNH - Free Report) , Inogen Inc. (INGN - Free Report) and Infinity Pharmaceuticals, Inc. . While Inogen and Infinity sport a Zacks Rank #1 (Strong Buy), UnitedHealth holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen posted positive surprises in three of the last four quarters with an average positive surprise of 49.08%.
Infinity delivered positive surprises in the trailing four quarters with an average beat of 28.38%.
UnitedHealth delivered positive surprises in last four quarters with an average beat of 3.80%.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public. Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>